Welcome to our dedicated page for IN8bio news (Ticker: INAB), a resource for investors and traders seeking the latest updates and insights on IN8bio stock.
IN8bio, Inc. (Nasdaq: INAB) is a clinical-stage biotechnology company pioneering the development of novel therapies aimed at treating various cancers. Using allogeneic, autologous, and genetically modified gamma-delta T cells, IN8bio is revolutionizing cancer treatment. The company’s mission is to create groundbreaking therapies that harness the power of the body’s immune system to target and destroy cancer cells.
IN8bio's robust portfolio includes several promising product candidates:
- INB-400: Aimed at treating newly diagnosed glioblastoma (GBM), this product is currently in a Phase 2 clinical trial.
- INB-100: Designed for patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, this therapy is under Phase 1 clinical trials.
- INB-200: Another promising candidate targeting GBM, it has shown encouraging preliminary clinical data at the 2024 ASCO Annual Meeting.
- Additional products, like INB-300 and INB-500, are in various stages of development targeting both solid and liquid tumors.
Recently, IN8bio disclosed significant advancements in the treatment of GBM, utilizing their innovative gamma-delta T cell-based adoptive cellular therapy. A peer-reviewed publication highlighted the strategy and future direction of their novel treatment methods.
Financially, IN8bio extends its cash runway into 2025, bolstered by additional capital from a private placement in December 2023. The company continues to pursue more funding to advance its clinical trials and achieve its milestones.
IN8bio's groundbreaking work has garnered attention in the biotech field, especially for its genetically modified gamma-delta T cells, which are the first to be advanced into clinical trials. The company’s approach shows great potential in improving progression-free survival (PFS) and overall survival (OS) rates for GBM and other cancers.
For investors and stakeholders, IN8bio provides exciting opportunities as it moves towards commercializing its therapies, aiming to address significant unmet medical needs in oncology. For more information, please visit IN8bio.
IN8bio (Nasdaq: INAB) announced the appointment of Urvashi Patel, Ph.D., as Vice President of Regulatory Affairs and Stacey Bilinski as Vice President of Clinical Operations. These appointments aim to enhance the company's clinical pipeline, with plans to file at least one new IND this year. Dr. Patel brings over 17 years of drug development experience, including cell therapy, while Ms. Bilinski has over 30 years in clinical operations. IN8bio is focused on developing innovative gamma-delta T cell therapies for cancer treatment.
IN8bio, a clinical-stage biopharmaceutical company, announced its presentations for upcoming April conferences. At the AACR Annual Meeting 2022 in New Orleans, Dr. Lawrence Lamb will discuss γδ T cell-based therapy for gliomas on April 11, and Dr. Lei Ding will address drug-resistant immunotherapy on April 13. Additionally, CEO William Ho will participate in a panel at the BIO Alabama Annual Conference 2022 on April 25.
IN8bio specializes in developing gamma-delta T cell therapies for tumors and is currently running Phase 1 trials for INB-200 and INB-100.
IN8bio, Inc. (Nasdaq: INAB) shared promising results from its ongoing Phase 1 trial of INB-100 for treating patients with high-risk acute myeloid leukemia (AML). All three patients treated showed durable remissions lasting 23.3, 21.0, and 9.3 months post-bone marrow transplant (BMT). The immune systems of patients were effectively reconstituted at six months, with no serious treatment-related adverse events reported. This update was presented at the European Society for Blood and Marrow Transplantation (EBMT) 48th Annual Meeting, indicating potential for further clinical advancements.
IN8bio reported promising clinical results for INB-200 and INB-100, showing a well-tolerated safety profile and extended progression-free survival in glioblastoma and leukemia patients, respectively. The company raised $40 million through an IPO to fund development of its gamma-delta T cell therapies. Financially, it ended 2021 with $37 million in cash, up from $18 million in 2020. However, it also faced a net loss of $14.7 million for the year. As the company continues to advance its clinical programs, it plans to file an IND for INB-400 and present at several upcoming scientific conferences.
IN8bio, Inc. (Nasdaq: INAB) announced its participation in several upcoming virtual and hybrid conferences in March 2022. Key events include the European Society for Medical Oncology Congress on March 7-8, featuring a presentation on engineered γδ T-cells, and the Cowen 42nd Annual Health Care Conference on March 7, where CEO William Ho will discuss the company overview. Additional presentations will take place at the Oppenheimer Healthcare Conference and the European Society for Blood and Marrow Transplantation meeting.
IN8bio, Inc. (Nasdaq: INAB), a biopharmaceutical company focused on gamma-delta T cell therapies, announced executive presentations at two upcoming events. The BIO CEO & Investor Conference will take place from February 14-17, 2022, featuring CEO Will Ho. Additionally, at the Next Generation CAR-TCR Summit in London on February 22-24, 2022, CSO Dr. Lawrence Lamb and COO Dr. Kate Rochlin will present relevant research on CAR-T cell therapies. IN8bio is advancing clinical trials for its lead products targeting glioblastoma and leukemia.
IN8bio (Nasdaq: INAB) announced that CEO William Ho will present at four virtual investor conferences in January 2022. Key events include:
- H.C. Wainwright & Co. BioConnect Conference: January 10-13
- Solebury Trout Management Access: January 10-13 & 18-20
- Biotech Showcase: January 10, 11:00 a.m. EST
- B. Riley Virtual Oncology Conference: January 27, 11:00 a.m. EST
IN8bio focuses on developing gamma-delta T cell therapies for cancers.
IN8bio, Inc. (Nasdaq: INAB) announced a promising update on INB-200, the first genetically modified gamma-delta T cell therapy in clinical trials for glioblastoma multiforme (GBM). Currently in a Phase 1 trial, Cohort 1 has completed dosing with no dose limiting toxicities or serious adverse events, while Cohort 2 is actively enrolling patients. Notably, all treated patients exceeded expected progression-free survival intervals, demonstrating a potential improvement in overall survival. The trial aims to assess safety, tolerability, and efficacy of the therapy combined with standard chemotherapy.
IN8bio has announced encouraging early results from its ongoing Phase 1 trial of INB-100, a gamma-delta T cell therapy for patients with acute myeloid leukemia (AML). Three patients have received treatment, all of whom remain in remission, with two achieving durable responses lasting over 1.5 years. The therapy demonstrated a manageable safety profile, with no significant adverse events reported. This trial aims to explore the efficacy of this novel treatment for patients undergoing haploidentical stem cell transplants, where relapse rates can be high.
IN8bio, Inc. (Nasdaq: INAB) has announced the promotion of Kate Rochlin, Ph.D., to Chief Operating Officer, effective immediately. Dr. Rochlin, who has been with IN8bio since August 2020, previously served as Vice President, Operations and Innovation. She will oversee multiple operational functions and will continue to lead early innovation programs. The company is advancing its gamma-delta T cell therapies aimed at treating solid and liquid tumors, utilizing its proprietary DeltEx platform. IN8bio is conducting two Phase 1 clinical trials for its lead product candidates.
FAQ
What is the current stock price of IN8bio (INAB)?
What is the market cap of IN8bio (INAB)?
What does IN8bio, Inc. do?
What are the main products of IN8bio?
What recent advancements has IN8bio made?
How is IN8bio funded?
What is the significance of IN8bio's gamma-delta T cells?
How can I learn more about IN8bio’s clinical trials?
What is INB-400?
Where is IN8bio headquartered?
Who can I contact for investor relations?
How does IN8bio contribute to cancer research?
